Cancer & Metabolism最新文献

筛选
英文 中文
Correction to: The role of deoxycholic acid in macrophage polarization and remodeling of the tumor microenvironment during colorectal adenoma-carcinoma transition. 修正:去氧胆酸在结直肠腺瘤-癌转化过程中巨噬细胞极化和肿瘤微环境重塑中的作用。
IF 5.9 3区 医学
Cancer & Metabolism Pub Date : 2026-09-02 DOI: 10.1186/s40170-026-00448-z
Yujing Liu, Jie Yin, Lu Lu, Jiashu Pan, Gaoxuan Shao, Yangxian Xu, Guang Ji, Hanchen Xu
{"title":"Correction to: The role of deoxycholic acid in macrophage polarization and remodeling of the tumor microenvironment during colorectal adenoma-carcinoma transition.","authors":"Yujing Liu, Jie Yin, Lu Lu, Jiashu Pan, Gaoxuan Shao, Yangxian Xu, Guang Ji, Hanchen Xu","doi":"10.1186/s40170-026-00448-z","DOIUrl":"10.1186/s40170-026-00448-z","url":null,"abstract":"","PeriodicalId":9418,"journal":{"name":"Cancer & Metabolism","volume":"14 1","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13539813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148879107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IL-6-driven metabolic reprogramming of the multiple myeloma microenvironment. il -6驱动的多发性骨髓瘤微环境代谢重编程。
IF 5.9 3区 医学
Cancer & Metabolism Pub Date : 2026-08-06 DOI: 10.1186/s40170-026-00451-4
María Matamala Montoya, Silke Eleveld, Esther A Zaal, Celia R Berkers
{"title":"IL-6-driven metabolic reprogramming of the multiple myeloma microenvironment.","authors":"María Matamala Montoya, Silke Eleveld, Esther A Zaal, Celia R Berkers","doi":"10.1186/s40170-026-00451-4","DOIUrl":"10.1186/s40170-026-00451-4","url":null,"abstract":"<p><strong>Background: </strong>Multiple myeloma is an aggressive plasma cell malignancy that remains incurable despite major therapeutic advances and depends on extensive metabolic remodeling to support malignant growth and drug resistance. Although tumor cell-intrinsic mechanisms of drug resistance are well characterized, the contribution of cells in the tumor microenvironment, particularly bone marrow stromal cells, to metabolic remodeling and therapeutic resistance remains poorly understood.</p><p><strong>Methods: </strong>We combined [U-<sup>13</sup>C]glucose tracing metabolomics with a metabolomics-compatible co-culture system of multiple myeloma and bone marrow stromal cells to assess the impact of co-culture on metabolic pathway activity across genetically distinct multiple myeloma cell lines. Cells were additionally subjected to cytokine analysis, gene expression analysis and drug response assays to investigate associations between metabolic changes, treatment responses and cytokine abundances.</p><p><strong>Results: </strong>Bone marrow stromal cell co-culture induced a convergent metabolic rewiring in multiple myeloma cells, enhancing pathways previously linked to bortezomib resistance, including glycolysis, tricarboxylic acid cycle activity, serine synthesis and nucleotide biosynthesis. In parallel, stromal cells acquired a cancer-associated fibroblast-like phenotype characterized by increased interleukin-6 and transforming growth factor-β production. This cytokine milieu promoted bortezomib resistance and stromal cell activation. Interleukin-6 alone was sufficient to rescue multiple myeloma cells from bortezomib-induced cytotoxicity and reproduced a substantial fraction of the co-culture-induced metabolic remodeling. Analysis of patient proteomics revealed a strong positive association between interleukin-6 abundance and expression of enzymes involved in mitochondrial metabolism, glycolysis, serine metabolism, nucleotide metabolism and redox homeostasis.</p><p><strong>Conclusions: </strong>These findings identify bone marrow stromal cell-derived interleukin-6 as a central driver of tumor microenvironment-mediated metabolic reprogramming and bortezomib resistance in multiple myeloma. Targeting interleukin-6-dependent metabolic signaling may represent a promising strategy to overcome stromal-driven therapeutic resistance.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9418,"journal":{"name":"Cancer & Metabolism","volume":"14 1","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13746571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic targeting of cyst(e)ine enhances carboplatin responsiveness in ovarian cancer. 卵巢囊肿(e)线的代谢靶向增强卡铂对卵巢癌的反应性。
IF 5.9 3区 医学
Cancer & Metabolism Pub Date : 2026-07-29 DOI: 10.1186/s40170-026-00450-5
Ina Yoon, Sinae Oh, Seo Young Park, Jisu Park, Hyelim Jang, Eunji Park, Kyung Ah You, Kibum Kim, Soonjae Hwang, Hyeong Yun Kim, Seongmin Cho, Jung Min Han, Sunghoon Kim
{"title":"Metabolic targeting of cyst(e)ine enhances carboplatin responsiveness in ovarian cancer.","authors":"Ina Yoon, Sinae Oh, Seo Young Park, Jisu Park, Hyelim Jang, Eunji Park, Kyung Ah You, Kibum Kim, Soonjae Hwang, Hyeong Yun Kim, Seongmin Cho, Jung Min Han, Sunghoon Kim","doi":"10.1186/s40170-026-00450-5","DOIUrl":"10.1186/s40170-026-00450-5","url":null,"abstract":"<p><strong>Background: </strong>Metabolic rewiring enables cancer cells to adapt to nutrient stress, making amino acid deprivation an attractive therapeutic strategy. However, cancer type-specific responsiveness to individual amino acid deprivation remains incompletely characterized.</p><p><strong>Methods: </strong>We profiled the viability of 60 cancer cell lines from six tissue origins under deprivation of each of the 20 proteinogenic amino acids. Based on the screening, we evaluated the therapeutic interaction between cyst(e)ine deprivation or pharmacological inhibition of cyst(e)ine metabolism and carboplatin in ovarian cancer models. Transcriptomic analyses together with functional validation experiments were performed to explore potential molecular mechanisms.</p><p><strong>Results: </strong>The unbiased screen revealed a relative sensitivity of ovarian cancer cells to cyst(e)ine deprivation. Cyst(e)ine starvation enhanced responsiveness to carboplatin in both carboplatin-sensitive and -resistant ovarian cancer cell lines. Pharmacological inhibition of cyst(e)ine metabolism showed a similar effect, supporting pharmacological targeting of cyst(e)ine metabolism as a potential alternative to dietary deprivation. Activating transcription factor 3 (ATF3) was identified as a candidate stress-responsive factor, and its suppression partially attenuated apoptotic marker induction, suggesting that ATF3 contributes, at least in part, to the stress-associated apoptotic response.</p><p><strong>Conclusion: </strong>These findings suggest that cyst(e)ine metabolism may represent a therapeutically relevant metabolic target for enhancing carboplatin response in ovarian cancer. This screening framework provides a systematic approach to identify amino acid-associated metabolic dependencies with potential relevance in cancer therapy.</p>","PeriodicalId":9418,"journal":{"name":"Cancer & Metabolism","volume":"14 1","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13700485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PKM2 modulation regulates leukemia cell survival. PKM2调控白血病细胞存活。
IF 5.9 3区 医学
Cancer & Metabolism Pub Date : 2026-07-24 DOI: 10.1186/s40170-026-00440-7
Nikolina Vrdoljak, Ekaterina N Parfenova, Alessia Roma, Drake A Mosca, Mark D Minden, Paul A Spagnuolo
{"title":"PKM2 modulation regulates leukemia cell survival.","authors":"Nikolina Vrdoljak, Ekaterina N Parfenova, Alessia Roma, Drake A Mosca, Mark D Minden, Paul A Spagnuolo","doi":"10.1186/s40170-026-00440-7","DOIUrl":"10.1186/s40170-026-00440-7","url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) cells exhibit aberrant metabolism defined by a shift away from oxidative phosphorylation and towards anaerobic glycolysis, favouring cell growth. Glycolytic enzymes are altered for this change to occur, including pyruvate kinase (PK), where the tetrameric and high activity M1 isoform (PKM1) is replaced with the predominantly dimeric and low activity M2 isoform (PKM2). Dimeric PKM2 produces less pyruvate and acts as a protein kinase in the nucleus, demonstrating divergent roles in both cell metabolism and as a transcriptional co-activator. In this study, the role of PKM2 in AML was defined, as PKM2 levels were elevated but PK enzymatic activity was reduced in AML cells compared to normal hematopoietic cells. Genetic and pharmacological studies show that decreasing and increasing PKM2 activity resulted in anti-AML effects both in vitro and in vivo. Indeed, these models show that inhibition and activation of PKM2 disrupt the native oligomeric state of the protein, resulting in reduced nuclear PKM2 accumulation and c-Myc expression, ultimately leading to cell death. Together, these results highlight the importance of PKM2 in AML, uncover the mechanisms by which both inhibition and activation cause AML cell death, and identify a novel modulator of PKM2 activity.</p>","PeriodicalId":9418,"journal":{"name":"Cancer & Metabolism","volume":"14 1","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13499311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Caloric restriction enhances radiosensitivity of colorectal tumors through the cGAS-STING pathway activation. 热量限制通过激活cGAS-STING通路增强结直肠肿瘤的放射敏感性。
IF 5.9 3区 医学
Cancer & Metabolism Pub Date : 2026-07-21 DOI: 10.1186/s40170-026-00449-y
Li-Li Zhang, Li-Qiang Qin, Li Ding, Wen-Yue Shan, Yu Zhao, Yu-Qi Zhang, Jia Gu, Lin Zhao, Kai-Yuan Hui, Yu-Song Zhang, Jia-Ying Xu
{"title":"Caloric restriction enhances radiosensitivity of colorectal tumors through the cGAS-STING pathway activation.","authors":"Li-Li Zhang, Li-Qiang Qin, Li Ding, Wen-Yue Shan, Yu Zhao, Yu-Qi Zhang, Jia Gu, Lin Zhao, Kai-Yuan Hui, Yu-Song Zhang, Jia-Ying Xu","doi":"10.1186/s40170-026-00449-y","DOIUrl":"10.1186/s40170-026-00449-y","url":null,"abstract":"<p><p>Although radiotherapy is an important clinical option for colorectal cancer, its efficacy is limited by intrinsic tumor radioresistance and radiation-induced toxicity in surrounding normal tissues. This study investigated the radiosensitizing effects of either 7-day 30% caloric restriction (CR) or 24-hour fasting in a murine model bearing CT-26 colorectal tumor and explored the underlying mechanisms. CR and fasting pretreatment enhanced irradiation-induced tumor apoptosis, mitochondrial dysfunction, and cytosolic DNA stress, leading to activation of the cyclic GMP-AMP synthase/stimulator of interferon gene (cGAS-STING) pathway, increased infiltration of tumor killing-associated CD8 + cytotoxic T lymphocytes, and modulation of macrophage polarization toward an antitumor phenotype. In addition, CR and fasting further suppressed the expression of glycolysis and lipid metabolism related proteins in the tumor microenvironment upon radiation exposure. By contrast, CR and fasting protected normal intestinal tissue from irradiation-induced damage. These findings were validated in vitro using CT-26 and normal small intestinal epithelial cells (IEC-6) cultured under medium with or without glucose. The critical role of the cGAS-STING pathway in enhancing radiosensitivity was confirmed through STING siRNA-mediated knockdown, combined with pharmacological intervention using the STING agonist MSA-2 and inhibitor H-151. In conclusion, our findings indicate that CR and fasting may increase the radiosensitivity of colorectal tumors, while reducing radiation injury to normal intestinal tissue.</p>","PeriodicalId":9418,"journal":{"name":"Cancer & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13678954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148547988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
VAV2 drives glycolytic reprogramming in esophageal squamous cell carcinoma via EIF3F-mediated MTA1 deubiquitination. VAV2通过eif3f介导的MTA1去泛素化驱动食管鳞状细胞癌糖酵解重编程。
IF 5.9 3区 医学
Cancer & Metabolism Pub Date : 2026-07-09 DOI: 10.1186/s40170-026-00447-0
Weiling Liu, Yangyang Hou, Bo Wang, Fengna Liu, Lu Zheng, Hailing Wang, Shaomei Li, Xiaowan Zhou, Mengting Zhang, Shujun Yang, Yan Zhao
{"title":"VAV2 drives glycolytic reprogramming in esophageal squamous cell carcinoma via EIF3F-mediated MTA1 deubiquitination.","authors":"Weiling Liu, Yangyang Hou, Bo Wang, Fengna Liu, Lu Zheng, Hailing Wang, Shaomei Li, Xiaowan Zhou, Mengting Zhang, Shujun Yang, Yan Zhao","doi":"10.1186/s40170-026-00447-0","DOIUrl":"10.1186/s40170-026-00447-0","url":null,"abstract":"<p><p>Despite therapeutic advances, esophageal squamous cell carcinoma (ESCC) remains lethal due to metabolic adaptation via aerobic glycolysis. Here we report that VAV2 functions as an oncoprotein promoting this metabolic switch in ESCC. VAV2 overexpression enhances glycolytic flux-evidenced by increased glucose uptake, lactate production, and ECAR-while reducing oxygen consumption. Mechanistically, VAV2 upregulates EIF3F expression, enabling EIF3F to deubiquitinate and stabilize MTA1, which subsequently activates HIF-1α and its downstream targets GLUT1 and LDHA. EIF3F knockdown attenuates VAV2-driven oncogenic phenotypes and tumor progression in xenograft models, validating this axis as a functional dependency. This study uncovers a \"signaling-deubiquitination-metabolism\" regulatory nexus in ESCC and provides rationale for targeting VAV2-EIF3F interaction to overcome glycolysis-dependent therapy resistance.</p>","PeriodicalId":9418,"journal":{"name":"Cancer & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13459262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fasting-mimicking diet counteracts gut microbial dysbiosis in experimental lynch syndrome. 模拟禁食饮食抵消实验性lynch综合征的肠道微生物失调。
IF 5.9 3区 医学
Cancer & Metabolism Pub Date : 2026-06-30 DOI: 10.1186/s40170-026-00446-1
Lorena Garcia-Castillo, Giulio Ferrero, Olga Blaževitš, Giulia Francescato, Azra Thaseen Eliass, Natalia E Cortez, Marc Beltrà, Sonia Tarallo, Barbara Pardini, Paola Costelli, Alessio Naccarati, Valter D Longo, Fabio Penna
{"title":"Fasting-mimicking diet counteracts gut microbial dysbiosis in experimental lynch syndrome.","authors":"Lorena Garcia-Castillo, Giulio Ferrero, Olga Blaževitš, Giulia Francescato, Azra Thaseen Eliass, Natalia E Cortez, Marc Beltrà, Sonia Tarallo, Barbara Pardini, Paola Costelli, Alessio Naccarati, Valter D Longo, Fabio Penna","doi":"10.1186/s40170-026-00446-1","DOIUrl":"10.1186/s40170-026-00446-1","url":null,"abstract":"<p><p>The development of colorectal cancer (CRC) is largely influenced by hereditary factors, with up to one-third of cases linked to genetic predisposition. In parallel, environmental factors such as diet and intestinal microbiota play a significant role. Lynch syndrome (LS), the most common form of hereditary CRC, is due to mutations in DNA mismatch repair genes. Diet interventions such as calorie restriction (CR) can modify the course of the disease, altering nutrient supply and promoting beneficial microbial populations. Fasting-mimicking diets (FMD) are plant-based CR regimens that showed promise in modulating the gut microbiota and suppressing CRC progression in pre-clinical ectopic cancer models. In this study, Villin-Cre/Msh2-floxed (VCM) mice, modelling LS, were subjected to periodic FMD cycles for 10 months. FMD regimen influenced animal weight in a sexually dimorphic manner, stably reducing animal body weight only in males. Moreover, shotgun metagenomic sequencing revealed that FMD mitigated the dysbiotic longitudinal changes associated with cancer onset, preserving beneficial species, such as Lactobacillus johnsonii, and reducing adverse species, such as Escherichia coli. Metabolic pathway analysis also showed significant differences, with FMD preventing the upregulation of pathways involved in amino acid and nucleotide synthesis, potentially promoting tumour growth. Overall, the findings suggest that periodic FMD may result useful in a multimodal approach for LS management, counteracting gut microbiota alterations.</p>","PeriodicalId":9418,"journal":{"name":"Cancer & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148359591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CRISPR screen identifies autophagy inhibition (GNS561) as a PARP inhibitor (AZD5305) combination strategy in small cell lung cancer. CRISPR筛选发现自噬抑制(GNS561)作为PARP抑制剂(AZD5305)在小细胞肺癌中的联合策略。
IF 5.9 3区 医学
Cancer & Metabolism Pub Date : 2026-06-24 DOI: 10.1186/s40170-026-00443-4
Tony Yu, Ranya Barayan, Lifang Song, Vidhyasagar Venkatasubramanian, Janvi Tamakuwala, Sree N Nair, Vivek Philip, Benjamin H Lok
{"title":"CRISPR screen identifies autophagy inhibition (GNS561) as a PARP inhibitor (AZD5305) combination strategy in small cell lung cancer.","authors":"Tony Yu, Ranya Barayan, Lifang Song, Vidhyasagar Venkatasubramanian, Janvi Tamakuwala, Sree N Nair, Vivek Philip, Benjamin H Lok","doi":"10.1186/s40170-026-00443-4","DOIUrl":"10.1186/s40170-026-00443-4","url":null,"abstract":"<p><strong>Background: </strong>Small cell lung cancer (SCLC) is a deadly cancer with few treatment options and poor prognosis, creating a dire need for improving therapies. Poly (ADP-ribose) polymerase inhibitors (PARPi) have been tested as a treatment strategy, but patient response varies. We aimed to identify novel approaches to sensitize SCLC to PARPi through a genome-wide CRISPR dropout screen.</p><p><strong>Methods: </strong>Genome-wide CRISPR dropout screening was conducted in two SCLC cell lines using the PARPi, olaparib, as the selection pressure. Stable shRNA-mediated knockdown cell lines were validated by Western blotting and tested for olaparib sensitivity by assaying for cell viability. Synergy between PARPi and autophagy inhibition was tested by treating SCLC cell lines and analyzing cell viability using SynergyFinder+. The therapeutic strategy combining AZD5305 (PARPi) and GNS561 (novel autophagy inhibitor) was tested in cell line-derived xenograft mouse models.</p><p><strong>Results: </strong>CRISPR screening identified the loss of mTOR negative regulators as a mechanism of PARPi sensitivity in SCLC, and knockdown of TSC1 and TSC2 sensitized SCLC cell lines to olaparib. Therapeutic strategies combining PARPi and autophagy inhibition demonstrated synergy in SCLC cell lines, and combination therapy with AZD5305 and GNS561 was effective in cell line-derived xenograft mouse models.</p><p><strong>Conclusions: </strong>Autophagy inhibition downstream of the mTOR pathway is a mechanism of PARPi sensitivity in SCLC. This suggests that a therapeutic combination of autophagy inhibition and PARPi is a promising treatment strategy in SCLC, paving the way for the adoption of novel treatments in this disease context.</p>","PeriodicalId":9418,"journal":{"name":"Cancer & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13551694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of alpha1-oleate as a potent regulator of adipokine-dependent metabolism, in bladder cancer tissue. 在膀胱癌组织中,α 1-油酸作为脂肪因子依赖性代谢的有效调节剂的鉴定。
IF 5.9 3区 医学
Cancer & Metabolism Pub Date : 2026-06-23 DOI: 10.1186/s40170-026-00445-2
Farhan Haq, Siddharth Chinchankar, Ines Ambite, Shahram Ahmadi, Hien Tran, Atefeh Nazari, Antonin Brisuda, Jaromir Hacek, Marek Babjuk, Catharina Svanborg
{"title":"Identification of alpha1-oleate as a potent regulator of adipokine-dependent metabolism, in bladder cancer tissue.","authors":"Farhan Haq, Siddharth Chinchankar, Ines Ambite, Shahram Ahmadi, Hien Tran, Atefeh Nazari, Antonin Brisuda, Jaromir Hacek, Marek Babjuk, Catharina Svanborg","doi":"10.1186/s40170-026-00445-2","DOIUrl":"10.1186/s40170-026-00445-2","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunctions are associated with increased cancer morbidity and rapid tumor progression. The alpha1-oleate complex has been used successfully to treat bladder cancer in a placebo-controlled Phase II study. Studies of the related BAMLET complexes recently identified effects on metabolism, suggesting additional functions of the \"HAMLET family\" of tumoricidal complexes.</p><p><strong>Aims: </strong>To investigate if intravesical alpha1-oleate treatment affects metabolism in bladder cancer tissue.</p><p><strong>Materials and methods: </strong>Samples were obtained from patients with NMIBC, enrolled in a placebo-controlled study of intravesical alpha1-oleate treatment [1]. Cells shed into the urine were harvested at each instillation and biopsies obtained at TURBT after six instillations of alpha1-oleate. The shed cells and biopsies were subjected to RNA sequencing and genome-wide transcriptomic analysis, and urine samples were analyzed using adipokine arrays.</p><p><strong>Results: </strong>RNA sequencing detected significant inhibition of metabolic genes and networks in shed cells and tissue biopsies from alpha1-oleate treated patients, compared to the placebo group. Genes and gene networks regulating glucose and lipid synthesis were inhibited in alpha1-oleate treated patients, including ADIPOQ, which encodes the lipid- and glucose-regulating protein adiponectin and LEP, which encodes the metabolism and fat storage regulator Leptin. Leptin was further identified as an upstream regulator of the adiponectin response to alpha1-oleate and LEP and ADIPOQ networks showed strong interconnection in treated tissues. Analysis of shed tumor cells, suggested rapid kinetics of the metabolic response and urine levels of adiponectin and leptin were increased post-treatment, compared to pre-treatment samples and the shed tumor cells in urine contained adiponectin and leptin, as shown by immunohistochemistry.</p><p><strong>Conclusions: </strong>The findings identify potent local effects of alpha1-oleate treatment on tumor metabolism, after intravesical instillation. The metabolic regulators adiponectin and leptin were affected in tumor tissue and cells containing adiponectin and leptin were shed into the urine, potentially depleting the tumor of cells with high adipokine levels. These potent effects suggest a new molecular approach for targeting and inhibiting key regulators of cancer metabolism in superficial tumors.</p><p><strong>Trial registration: </strong>Doubleblinded Phase I/II clinical trial (EudraCT 201600426914 NCT03560479, Registration Date 20180521).</p>","PeriodicalId":9418,"journal":{"name":"Cancer & Metabolism","volume":"14 1","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13292342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DLL1-mediated ferroptosis resistance via the Notch-Nrf2/GPX4 axis drives cisplatin resistance in ovarian cancer. dll1通过Notch-Nrf2/GPX4轴介导的铁下垂耐药驱动卵巢癌顺铂耐药。
IF 5.9 3区 医学
Cancer & Metabolism Pub Date : 2026-06-17 DOI: 10.1186/s40170-026-00444-3
Dan Ye, Gaoting Huang, Xingcheng Yan, Lezi Suntan, Haoran Shen, Jian Shen
{"title":"DLL1-mediated ferroptosis resistance via the Notch-Nrf2/GPX4 axis drives cisplatin resistance in ovarian cancer.","authors":"Dan Ye, Gaoting Huang, Xingcheng Yan, Lezi Suntan, Haoran Shen, Jian Shen","doi":"10.1186/s40170-026-00444-3","DOIUrl":"10.1186/s40170-026-00444-3","url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer (OV) is a leading cause of cancer-related mortality, with cisplatin resistance being a major clinical challenge. This study investigates the role of the Notch ligand DLL1 in mediating ferroptosis resistance and its impact on cisplatin sensitivity in OV.</p><p><strong>Methods: </strong>Multi-omics data, clinical samples, and OV cell lines were used to assess DLL1 expression, its link to prognosis, and its effect on the Nrf2/GPX4 axis. CCK-8, clone formation, and ferroptosis assays evaluated the impact of DLL1 on cell behavior and cisplatin sensitivity.</p><p><strong>Results: </strong>DLL1 was upregulated in OV tissues and correlated with poor prognosis. Its knockdown inhibited cell proliferation, migration, and EMT, while inducing ferroptosis, evidenced by increased lipid peroxidation and mitochondrial dysfunction. Mechanistically, DLL1 activated the Nrf2/GPX4 antioxidant axis. DLL1 depletion sensitized OV cells to cisplatin. In vivo, combining DLL1-targeted therapy with a ferroptosis inducer significantly reduced tumor growth in cisplatin-resistant models.</p><p><strong>Conclusion: </strong>DLL1 drives cisplatin resistance in OV by enhancing ferroptosis resistance via the Notch-Nrf2/GPX4 axis. Targeting DLL1 alongside ferroptosis induction represents a promising therapeutic strategy, positioning DLL1 as a potential biomarker and target in drug-resistant OV.</p>","PeriodicalId":9418,"journal":{"name":"Cancer & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13520430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148270363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书